Immuron Improves Hadasit Royalty Terms
Filed with ASX · · 1 page · English
Earlier from Immuron
- Appendix 4D - Half Yearly Report and Accounts
- Immuron Initiates Pre-Clinical Colitis Development Program
- Immuron Secures upto $1.7M Equity & Convertible Note Funding
- Immuron Receives $1.47M R&D Tax Concession Refund
- Analyst Reports on Immuron IMM-529 C. difficile Program
Later from Immuron
- Expansion of US Travelan Sales Following CVS Pharmacy Launch
- US Travelan Sales Network Widened by Allocation Inc Ptnrship
- US Distribution Reach Expanded through McKesson
- Immuron Announces E-Commerce Agreement with QBID in China
- NASH Phase II Trial Reaches 50% Recruitment Milestone
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron